Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 295Carcinoma, Non-Small-Cell Lung 160Lung Neoplasms 89Breast Neoplasms 84Urinary Bladder Neoplasms 83Cholangiocarcinoma 58Neoplasms 53Neoplasm Metastasis 51Ovarian Neoplasms 45Biliary Tract Neoplasms 45Lymphoma, Large B-Cell, Diffuse 32Lymphoma 30Sarcoma 29Hodgkin Disease 28Recurrence 26Nasopharyngeal Carcinoma 26Gallbladder Neoplasms 26Carcinoma, Transitional Cell 26Adenocarcinoma 22Triple Negative Breast Neoplasms 20Fallopian Tube Neoplasms 20Bile Duct Neoplasms 20Adenocarcinoma of Lung 20Carcinoma, Renal Cell 17Carcinoma, Ovarian Epithelial 16Urethral Neoplasms 15Lymphoma, Non-Hodgkin 15Colorectal Neoplasms 14Leiomyosarcoma 13Kidney Neoplasms 13

Interventions

Tegafur 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Stage IA Pancreatic Adenocarcinoma × Gemcitabine × Clear all
NCT04216758 2020-06-30

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Fudan University

Phase 2 Unknown
300 enrolled
Gastrointestinal

Stage IA Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡